IDEAYA plans Phase 3 trial of IDE849 in refractory neuroendocrine carcinomas by end-2026
IDYA•IDEAYA Biosciences plans to launch IDE849 registration trials by the end of 2026 after discussions with the FDA. A single-arm cohort of about 90 previously treated patients could support accelerated approval, while randomized Phase 3 trials are planned to confirm benefit and evaluate the drug in extensive-stage small cell lung cancer after Imdelltra treatment.
1. Planned trial designs
IDEAYA Biosciences plans a single-arm study of approximately 90 previously treated gastroenteropancreatic neuroendocrine carcinoma patients that could support accelerated approval, alongside a randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes to confirm clinical benefit. A separate randomized Phase 3 trial will evaluate IDE849 in extensive-stage small cell lung cancer following Imdelltra treatment; results presented at ESMO in October showed tumor responses and a favorable safety profile.



